4-amino-1-ethyl-3-propyl-1H-pyrazole-5-carboxamide | 139756-19-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 4-amino-1-ethyl-3-propyl-1H-pyrazole-5-carboxamide
• 英文别名: 4-amino-1-ethyl-3-propylpyrazole-5-carboxamide；4-amino-1-ethyl-3-propyl-1H-5-pyrazolecarboxamide；4-amino-1-ethyl-3-n-propylpyrazole-5-carboxamide；1-Ethyl-3-n-propyl-4-aminopyrazole-5-formamide；4-amino-2-ethyl-5-propylpyrazole-3-carboxamide
• CAS: 139756-19-7
• 化学式: C₉H₁₆N₄O
• 分子量: 196.252
• InChiKey: RPICWPGZIWKHRX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  86.9
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-amino-1-ethyl-3-propyl-1H-pyrazole-5-carboxamide 、 邻乙氧基苯甲酰氯 以73%的产率得到4-(2-Ethoxybenzamido)-1-ethyl-3-n-propylpyrazole-5-carboxamide
  参考文献：
  名称：

  Method of treating a patient having precancerous lesions with phenyl purinone derivatives

  摘要：

  苯基嘌呤酮衍生物对于治疗患有癌前病变的患者非常有用。这些化合物还可用于抑制肿瘤细胞的生长。

  公开号：

  US06200980B1
• 作为产物：
  描述：

  1-ethyl-4-nitro-3-propyl-1H-5-pyrazolecarboxamide 以100%的产率得到4-amino-1-ethyl-3-propyl-1H-pyrazole-5-carboxamide
  参考文献：
  名称：

  Method of treating a patient having precancerous lesions with phenyl purinone derivatives

  摘要：

  苯基嘌呤酮衍生物对于治疗患有癌前病变的患者非常有用。这些化合物还可用于抑制肿瘤细胞的生长。

  公开号：

  US06200980B1

文献信息

• Pyrazolopyrimidinone antianginal agents
  申请人：Pfizer Inc.

  公开号：US05250534A1

  公开（公告）日：1993-10-05

  Compounds of the formula: ##STR1## wherein R.sup.1 is H, C.sub.1 -C.sub.3 alkyl, C.sub.3 -C.sub.5 cycloalkyl or C.sub.1 -C.sub.3 perfluoroalkyl; R.sup.2 is H, C.sub.1 -C.sub.6 alkyl optionally substituted by OH, C.sub.1 -C.sub.3 alkoxy or C.sub.3 -C.sub.6 cycloalkyl, or C.sub.1 -C.sub.3 perfluoroalkyl; R.sup.3 is C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 alkenyl, C.sub.3 -C.sub.6 alkynyl, C.sub.3 -C.sub.7 cycloalkyl, C.sub.1 -C.sub.6 perfluoroalkyl or (C.sub.3 -C.sub.6 cycloalkyl)C.sub.1 -C.sub.6 alkyl; R.sup.4 taken together with the nitrogen atom to which it is attached completes a pyrrolidinyl, piperidino, morpholino, or 4-N-(R.sup.6)-piperazinyl group; R.sup.5 is H, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.3 alkoxy, NR.sup.7 R.sup.8, or CONR.sup.7 R.sup.8 ; R.sup.6 is H, C.sub.1 -C.sub.6 alkyl, (C.sub.1 -C.sub.3 alkoxy) C.sub.2 - C.sub.6 alkyl, hydroxy C.sub.2 -C.sub.6 alkyl, (R.sup.7 R.sup.8 N)C.sub.2 -C.sub.6 alkyl, (R.sup.7 R.sup.8 NCO)C.sub.1 -C.sub.6 alkyl, CONR.sup.7 R.sup.8, CSNR.sup.7 R.sup.8 or C(NH)NR.sup.7 R.sup.8 ; R.sup.7 and R.sup.8 are each independently H, C.sub.1 -C.sub.4 alkyl, (C.sub.1 -C.sub.3 alkoxy)C.sub.2 -C.sub.4 alkyl or hydroxy C.sub.2 -C.sub.4 alkyl; and pharmaceutically acceptable salts thereof, are selective cGMP PDE inhibitors useful in the treatment of cardiovascular disorders such as angina, hypertension, heart failure and atherosclerosis.

  该化合物的结构式为：##STR1## 其中R.sup.1为H，C.sub.1 -C.sub.3烷基，C.sub.3 -C.sub.5环烷基或C.sub.1 -C.sub.3全氟烷基；R.sup.2为H，C.sub.1 -C.sub.6烷基，可以选择性地被OH，C.sub.1 -C.sub.3烷氧基或C.sub.3 -C.sub.6环烷基，或C.sub.1 -C.sub.3全氟烷基取代；R.sup.3为C.sub.1 -C.sub.6烷基，C.sub.3 -C.sub.6烯基，C.sub.3 -C.sub.6炔基，C.sub.3 -C.sub.7环烷基，C.sub.1 -C.sub.6全氟烷基或(C.sub.3 -C.sub.6环烷基)C.sub.1 -C.sub.6烷基；R.sup.4与其连接的氮原子一起形成吡咯啉基、哌啶基、吗啉基或4-N-(R.sup.6)-哌嗪基；R.sup.5为H，C.sub.1 -C.sub.4烷基，C.sub.1 -C.sub.3烷氧基，NR.sup.7 R.sup.8，或CONR.sup.7 R.sup.8；R.sup.6为H，C.sub.1 -C.sub.6烷基，(C.sub.1 -C.sub.3烷氧基)C.sub.2 - C.sub.6烷基，羟基C.sub.2 -C.sub.6烷基，(R.sup.7 R.sup.8 N)C.sub.2 -C.sub.6烷基，(R.sup.7 R.sup.8 NCO)C.sub.1 -C.sub.6烷基，CONR.sup.7 R.sup.8，CSNR.sup.7 R.sup.8或C(NH)NR.sup.7 R.sup.8；R.sup.7和R.sup.8各自独立地为H，C.sub.1 -C.sub.4烷基，(C.sub.1 -C.sub.3烷氧基)C.sub.2 -C.sub.4烷基或羟基C.sub.2 -C.sub.4烷基；以及其药学上可接受的盐，是用于治疗心血管疾病如心绞痛、高血压、心力衰竭和动脉粥样硬化的选择性cGMP PDE抑制剂。
• A facile one step synthesis of 1,6 -dihydro-7<i>H</i>-pyrazolo[4,3-<i>d</i>]-pyrimidin-7-ones
  作者：Nalla Ram Reddy、Ghanta Mahesh Reddy、Battu Saida Reddy、Padi Pratap Reddy

  DOI：10.1002/jhet.5570420502

  日期：2005.7

  A general synthetic approach to pyrazolo[4,3-d]pyrimidines is reported. Aldehydes, arylideneanilines, carboxylic acids and orthoesters are used as one-carbon units for bridging the two amino functions of 4-amino-1-alkyl-3-propylpyrazole-5-carboxamides.

  报道了吡唑并[4，3- d ]嘧啶的一般合成方法。醛，芳基苯胺，羧酸和原酸酯用作连接4-氨基-1-烷基-3-丙基吡唑-5-羧酰胺的两个氨基官能团的一个碳单元。
• A new entry to pyrazolo[4,3-<i>e</i>][1,4]diazepines. Facile synthesis of pyrazolo [4,3-<i>e</i>][1,4]diazepin-5,8-diones, 5,6,8-triones and pyrazolo[4,3-<i>e</i>]pyrrolo-[1,2-<i>a</i>][1,4]diazepin-5,10-diones
  作者：Nalla Ram Reddy、Ghanta Mahesh Reddy、Padi Pratap Reddy

  DOI：10.1002/jhet.5570420429

  日期：2005.5

  A facile approach to pyrazolo[4,3-e][1,4]diazepin-5,8-diones and pyrazolo[4,3-e]pyrrolo[1,2-a][1,4]-diazepin-5,10-diones is reported. Strategy involved the utility of α-amino acid as a three-atom segment in the construction of diazepine skeleton on the preformed pyrazole ring.

  吡唑并[4,3- e ] [1,4] diazepin-5,8-diones和吡唑并[4,3- e ] pyrrolo [1,2- a ] [1,4] -diazepin-5的简便方法据报道，有10-二酮。策略涉及在预先形成的吡唑环上构建二氮杂skeleton骨架时，将α-氨基酸用作三个原子的片段。
• Intermediates useful in the synthesis of pyrazolopyrimidinone
  申请人：Pfizer Inc.

  公开号：US05719283A1

  公开（公告）日：1998-02-17

  Compounds of the formula ##STR1## wherein R.sup.1 is H, C.sub.1 -C.sub.3 alkyl, C.sub.3 -C.sub.5 cycloalkyl or C.sub.1 -C.sub.3 perfluoroalkyl; R.sup.2 is H, C.sub.1 -C.sub.6 alkyl optionally substituted by OH, C.sub.1 -C.sub.3 alkoxy or C.sub.3 -C.sub.6 cycloalkyl, or C.sub.1 -C.sub.3 perfluoroalkyl; R.sup.3 is H, C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 alkenyl, C.sub.3 -C.sub.6 alkynyl, C.sub.3 -C.sub.7 cycloalkyl, C.sub.1 -C.sub.6 perfluoroalkyl or (C.sub.3 -C.sub.6 cycloalkyl)C.sub.1 -C.sub.6 alkyl; and Y is chloro, bromo, or fluoro. The above compounds are intermediates useful in the synthesis of certain pyrazolopyrimidinones which inhibit cyclic guanosine 3', 5'-monophosphate phosphodiesterase.

  化合物的公式为##STR1##其中R.sup.1是H，C.sub.1-C.sub.3烷基，C.sub.3-C.sub.5环烷基或C.sub.1-C.sub.3全氟烷基；R.sup.2是H，C.sub.1-C.sub.6烷基，可选择性地被OH，C.sub.1-C.sub.3烷氧基或C.sub.3-C.sub.6环烷基或C.sub.1-C.sub.3全氟烷基取代，或者C.sub.1-C.sub.3全氟烷基；R.sup.3是H，C.sub.1-C.sub.6烷基，C.sub.3-C.sub.6烯基，C.sub.3-C.sub.6炔基，C.sub.3-C.sub.7环烷基，C.sub.1-C.sub.6全氟烷基或(C.sub.3-C.sub.6环烷基)C.sub.1-C.sub.6烷基；Y是氯，溴或氟。上述化合物是合成某些嘧啶并嘧啶酮的中间体，这些嘧啶并嘧啶酮可以抑制环鸟苷3'，5'-单磷酸酯酶。
• Pyrazolopyrimidinethione Derivatives, Salts and Solvates Thereof, Preparation Methods and Use Thereof
  申请人：Li Shuxin

  公开号：US20070219220A1

  公开（公告）日：2007-09-20

  The present invention disclosed the pyrazolopyrimidinethione derivatives, salts and solvates thereof, preparation methods and use thereof. The pyrazolopyrimidinethione derivatives according to the present invention possess the structure of general formula I, wherein, R 1 , R 2 , R 3 , and R 4 represent alkyl, alkenyl, or aryl; R 5 represents hydrogen, alkyl, alkenyl, alkoxy, cycloalkyloxy, aryl, or alkylacyl; and R 6 represents hydrogen, alkyl, alkenyl, cycloalkyloxy, or alkylacyl. The pharmaceuticals containing the compound of the present invention and used for the treatment of impotence and sexlessness have the advantages of high selectivity over PDE V, long action time, and less side reactions, and the pharmaceuticals will arouse no side reactions of blood pressure decreasing and heart rate increasing, and it has broad market propect.

  本发明揭示了吡唑并嘧啶硫醇衍生物、其盐和溶剂化物、制备方法及其用途。根据本发明，吡唑并嘧啶硫醇衍生物具有一般式I的结构，其中，R1、R2、R3和R4代表烷基、烯基或芳基；R5代表氢、烷基、烯基、烷氧基、环烷氧基、芳基或烷基酰基；R6代表氢、烷基、烯基、环烷氧基或烷基酰基。含有本发明化合物的制药产品用于治疗阳痿和性冷淡具有高选择性PDE V、长效时间和副作用少的优点，并且不会引起血压降低和心率增加的副作用，具有广阔的市场前景。